Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:48.792Z.
Consensus retrieved: 2026-10-06T12:46:08.474Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:48.792Z.
Quote observation: 2026-10-06T15:53:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43
Forward PE Ratio (N/A) = Dated Quote Price ($96.20) / Consensus Forward EPS ($-9.52)
FORWARD PE RATIO
N/A
Inhibrx Biosciences Inc.
Market Cap
$1.41B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.41B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 29.21 |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.37B | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 17.70 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | N/A |
| Omeros Corporation (OMER)vs › | $1.35B | 20.54 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $96.20, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-9.52 | $-10.45 – $-8.58 | 2 | n/m |
| 2027-12-31 | $-8.94 | $-9.76 – $-8.10 | 2 | n/m |
| 2028-12-31 | $-5.42 | $-6.07 – $-4.77 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
